Vadim M.

Vadim M. serves as Senior Director of Translational Biology at Xencor since November 2024, following an extensive tenure at Rigel Pharmaceuticals Inc. from March 2002 to June 2024, where Vadim held the position of Executive Director of Translational Biology. Key achievements include developing the narrative for repurposing fostamatinib for COVID-19, securing multimillion-dollar funding from the Department of Defense for a phase 3 trial, and contributing to clinical developments of IRAK1/4 inhibitors. Notable roles also spanned leadership and scientific contributions to various small molecule projects leading to FDA approvals, as well as conducting comprehensive analyses on drug candidates and generating regulatory documentation. Earlier positions include a scientist role at GeneSoft Pharmaceuticals and postdoctoral research at Howard Hughes Medical Institute at UCLA, complemented by a PhD in Biochemistry and an MS in Chemistry from Lomonosov Moscow State University.